{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:09:46Z","timestamp":1780398586831,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence for disease-modifying therapies in patients with multiple sclerosis (MS) aged over 50 years is limited because this population is often excluded from randomized trials. With aging, MS increasingly reflects progression independent of relapse activity (PIRA), while adverse event risk increases. Cladribine is an immune reconstitution therapy with established efficacy in younger populations, but real-world data in older patients, particularly after prior high-efficacy therapies, are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective observational study of 95 patients aged over 50 years with active MS treated with cladribine at a tertiary MS center in Giessen, Germany. Patients were stratified by prior therapy (treatment-na\u00efve, platform therapy, high-efficacy therapy). Outcomes included relapses, MRI activity, confirmed disability worsening (CDW), confirmed disability improvement (CDI), no evidence of disease activity (NEDA-3\/4), lymphocyte dynamics, adverse events, and serum neurofilament light chain (NfL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age was 55.9\u2009\u00b1\u20094.1 years, baseline EDSS was 2.5\u2009\u00b1\u20091.0. Total follow-up duration was 137 patient-years. Annualized relapse rate decreased from 0.66 before treatment to 0.044 during follow-up. Six relapses and six new T2 lesions (each 6.3%) occurred during follow-up. CDW was observed in 10 patients (11.8%), while 21 patients (24.7%) showed sustained CDI. NEDA-3 was achieved by 66 patients (77.6%) and NEDA-4 by 65 patients (76.5%). No clear differences between prior-treatment groups were observed. Serum NfL levels decreased during treatment. Lymphopenia was predominantly grade I\u2013II. Infections were infrequent (27.4%) and mostly mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cladribine showed sustained effectiveness and an acceptable safety profile in MS patients over 50 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-026-00502-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:22:51Z","timestamp":1780395771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of cladribine tablets in patients with MS beyond the age of 50: experiences from a large tertiary German centre"],"prefix":"10.1186","volume":"8","author":[{"given":"Franziska","family":"Axhausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Baumgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borros","family":"Arneth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mrochen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun H.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"7","key":"502_CR1","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1007\/s00415-024-12384-3","volume":"271","author":"KA DiMauro","year":"2024","unstructured":"DiMauro, K. A., Swetlik, C., & Cohen, J. A. (2024). Management of multiple sclerosis in older adults: review of current evidence and future perspectives. Journal Of Neurology, 271(7), 3794\u20133805.","journal-title":"Journal Of Neurology"},{"issue":"3","key":"502_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40120-024-00603-y","volume":"13","author":"J de Seze","year":"2024","unstructured":"de Seze, J., Dive, D., Ayrignac, X., Castelnovo, G., Payet, M., Rayah, A., et al. (2024). Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis. Neurol Ther, 13(3), 519\u2013533.","journal-title":"Neurol Ther"},{"issue":"13","key":"502_CR3","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1177\/1352458520988637","volume":"27","author":"F Dahlke","year":"2021","unstructured":"Dahlke, F., Arnold, D. L., Aarden, P., Ganjgahi, H., Haring, D. A., Cuklina, J., et al. (2021). Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation. Multiple Sclerosis (Houndmills, Basingstoke, England), 27(13), 2062\u20132076.","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"9","key":"502_CR4","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin, F. D., Haring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., Cuklina, J., et al. (2022). How patients with multiple sclerosis acquire disability. Brain, 145(9), 3147\u20133161.","journal-title":"Brain"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"942796","DOI":"10.3389\/fimmu.2022.942796","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Dong, C., Han, Y., Gu, Z., & Sun, C. (2022). Immunosenescence, aging and successful aging. Frontiers In Immunology, 13, 942796.","journal-title":"Frontiers In Immunology"},{"issue":"1","key":"502_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s42466-021-00140-1","volume":"3","author":"H Wiendl","year":"2021","unstructured":"Wiendl, H., Gold, R., & Zipp, F. (2021). Multiple Sclerosis Therapy Consensus G. Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. Neurol Res Pract, 3(1), 44.","journal-title":"Neurol Res Pract"},{"issue":"5","key":"502_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Soelberg Sorensen, P., et al. (2010). A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal Of Medicine, 362(5), 416\u2013426.","journal-title":"New England Journal Of Medicine"},{"issue":"2","key":"502_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/13524585211012227","volume":"28","author":"S Pfeuffer","year":"2022","unstructured":"Pfeuffer, S., Rolfes, L., Hackert, J., Kleinschnitz, K., Ruck, T., Wiendl, H., et al. (2022). Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(2), 257\u2013268.","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"502_CR9","doi-asserted-by":"publisher","first-page":"175628642513428","DOI":"10.1177\/17562864251342855","volume":"18","author":"F Buttari","year":"2025","unstructured":"Buttari, F., Dolcetti, E., Rizzo, F. R., Rizzi, C., Lauritano, G., Borrelli, A., et al. (2025). Cladribine tablets in the new multiple sclerosis era. Therapeutic Advances In Neurological Disorders, 18, 17562864251342855.","journal-title":"Therapeutic Advances In Neurological Disorders"},{"key":"502_CR10","doi-asserted-by":"publisher","first-page":"104491","DOI":"10.1016\/j.msard.2022.104491","volume":"70","author":"PS Sorensen","year":"2023","unstructured":"Sorensen, P. S., Pontieri, L., Joensen, H., Heick, A., Rasmussen, P. V., Schafer, J., et al. (2023). Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study. Mult Scler Relat Disord, 70, 104491.","journal-title":"Mult Scler Relat Disord"},{"key":"502_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42466-019-0005-5","volume":"1","author":"RA Linker","year":"2019","unstructured":"Linker, R. A., & Chan, A. (2019). Navigating choice in multiple sclerosis management. Neurol Res Pract, 1, 5.","journal-title":"Neurol Res Pract"},{"issue":"2","key":"502_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., et al. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, 17(2), 162\u2013173.","journal-title":"Lancet Neurology"},{"issue":"Pt 9","key":"502_CR13","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","volume":"139","author":"J Lorscheider","year":"2016","unstructured":"Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., et al. (2016). Defining secondary progressive multiple sclerosis. Brain, 139(Pt 9), 2395\u20132405.","journal-title":"Brain"},{"issue":"1","key":"502_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42466-021-00139-8","volume":"3","author":"A Bayas","year":"2021","unstructured":"Bayas, A., Berthele, A., Hemmer, B., Warnke, C., & Wildemann, B. (2021). Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders. Neurol Res Pract, 3(1), 45.","journal-title":"Neurol Res Pract"},{"issue":"1","key":"502_CR15","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1038\/s41467-024-49309-7","volume":"15","author":"J Kramer","year":"2024","unstructured":"Kramer, J., Balloff, C., Weise, M., Koska, V., Uthmeier, Y., Esderts, I., et al. (2024). Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis. Nature Communications, 15(1), 5243.","journal-title":"Nature Communications"},{"issue":"8","key":"502_CR16","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1177\/13524585251345317","volume":"31","author":"E Portaccio","year":"2025","unstructured":"Portaccio, E., Betti, M., De Meo, E., Pasto, L., Razzolini, L., Patti, F., et al. (2025). Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 31(8), 985\u2013994.","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"12","key":"502_CR17","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni, G., Soelberg Sorensen, P., Cook, S., Rammohan, K., Rieckmann, P., Comi, G., et al. (2018). Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis (Houndmills, Basingstoke, England), 24(12), 1594\u20131604.","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"502_CR18","doi-asserted-by":"publisher","first-page":"103490","DOI":"10.1016\/j.msard.2022.103490","volume":"58","author":"G Disanto","year":"2022","unstructured":"Disanto, G., Moccia, M., Sacco, R., Spiezia, A. L., Carotenuto, A., Brescia Morra, V., et al. (2022). Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. Mult Scler Relat Disord, 58, 103490.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"502_CR19","first-page":"205521732513218","volume":"11","author":"J de Seze","year":"2025","unstructured":"de Seze, J., Zecca, C., Castelnovo, G., Ayrignac, X., Vermersch, P., Gobbi, C., et al. (2025). European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment? Mult Scler J Exp Transl Clin, 11(1), 20552173251321810.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"502_CR20","doi-asserted-by":"publisher","first-page":"e200415","DOI":"10.1212\/NXI.0000000000200415","volume":"12","author":"T Guerra","year":"2025","unstructured":"Guerra, T., Copetti, M., Zanetta, C., Patti, F., Chisari, C. G., Barbuti, E., et al. (2025). The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies Evaluation. Neurol Neuroimmunol Neuroinflamm, 12(4), e200415.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"502_CR21","doi-asserted-by":"publisher","first-page":"123070","DOI":"10.1016\/j.jns.2024.123070","volume":"462","author":"A Manni","year":"2024","unstructured":"Manni, A., Oggiano, F., Palazzo, C., Panetta, V., Gargano, C. D., Mangialardi, V., et al. (2024). Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing. Journal Of The Neurological Sciences, 462, 123070.","journal-title":"Journal Of The Neurological Sciences"},{"issue":"3","key":"502_CR22","doi-asserted-by":"publisher","first-page":"e213744","DOI":"10.1212\/WNL.0000000000213744","volume":"105","author":"C Robin","year":"2025","unstructured":"Robin, C., Rollot, F., Lefort, M., Casey, R., Vukusic, S., Mathey, G., et al. (2025). Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis. Neurology, 105(3), e213744.","journal-title":"Neurology"},{"key":"502_CR23","unstructured":"Sguigna, P. O. A., & Kaplan, J. Two-Year Findings on the Safety and Efficacy of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Trial). ACTRIMS; February 27-March 1; West Palm Beach, Florida 2024."},{"key":"502_CR24","doi-asserted-by":"publisher","first-page":"763433","DOI":"10.3389\/fimmu.2021.763433","volume":"12","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni, G., Coyle, P. K., Vermersch, P., Walker, B., Aldridge, J., Nolting, A., et al. (2021). Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. Frontiers In Immunology, 12, 763433.","journal-title":"Frontiers In Immunology"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-026-00502-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:22:54Z","timestamp":1780395774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42466-026-00502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1186\/s42466-026-00502-7","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave written informed consent. The study was approved by the local ethical committee (Ethical board of the Medical Faculty of the Justus-Liebig-University Giessen; 53\/23).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"F. Axhausen: has no conflict of interest to declare. S. Wolff: received lecturing honoraria from Mylan and Novartis, personal fees from Roche and research support from Novartis. R. Baumgart: received travel reimbursements from Sanofi B. Arneth: has no conflict of interest to declare. A. Mrochen: declares that there are no conflicts of interest in connection with this study, she received honoraria for lectures or consultancy from Alexion, Roche and Novartis and travel expenses to attend meetings from Alexion. H.H. Kraemer: received honoraria for lectures or consultancy work from Argenx, Alexion, J&J, Amgen, UCB, Roche, Novartis, travel expenses to attend meetings from Alexion, Sanofi and Grifols and research support from Roche and Argenx. S. Pfeuffer: received honoraria for lectures or consultation from Alexion, ArgenX, Biogen, Hexal, JUVISE, Merck Healthcare, neuraxpharm, Novartis, Roche and Sanofi, travel reimbursements from Alexion, Biogen, neuraxpharm, Novartis, Roche and Sanofi and research support from Biogen, Merck Healthcare and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}